United Bank Has $1.68 Million Stake in Medtronic PLC $MDT

United Bank raised its position in shares of Medtronic PLC (NYSE:MDT) by 132.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,352 shares of the medical technology company’s stock after acquiring an additional 11,015 shares during the period. United Bank’s holdings in Medtronic were worth $1,677,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. ARQ Wealth Advisors LLC increased its stake in shares of Medtronic by 478.2% in the first quarter. ARQ Wealth Advisors LLC now owns 26,983 shares of the medical technology company’s stock worth $2,338,000 after purchasing an additional 22,316 shares during the period. Diversify Wealth Management LLC boosted its stake in Medtronic by 51.6% during the 1st quarter. Diversify Wealth Management LLC now owns 98,447 shares of the medical technology company’s stock valued at $7,814,000 after purchasing an additional 33,500 shares during the period. Valmark Advisers Inc. boosted its stake in Medtronic by 20.5% during the 1st quarter. Valmark Advisers Inc. now owns 5,663 shares of the medical technology company’s stock valued at $491,000 after purchasing an additional 965 shares during the period. Carnegie Investment Counsel grew its holdings in Medtronic by 64.3% in the 1st quarter. Carnegie Investment Counsel now owns 6,421 shares of the medical technology company’s stock valued at $556,000 after buying an additional 2,513 shares during the last quarter. Finally, 180 Wealth Advisors LLC grew its holdings in Medtronic by 3.1% in the 1st quarter. 180 Wealth Advisors LLC now owns 39,773 shares of the medical technology company’s stock valued at $3,446,000 after buying an additional 1,211 shares during the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Stock Performance

Medtronic stock traded up $1.39 during trading hours on Friday, hitting $83.78. The stock had a trading volume of 7,190,992 shares, compared to its average volume of 8,643,010. The company has a 50-day moving average of $79.11 and a two-hundred day moving average of $88.53. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a market cap of $107.24 billion, a PE ratio of 22.46, a price-to-earnings-growth ratio of 2.25 and a beta of 0.56.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.01. The company had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.Medtronic’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities research analysts anticipate that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be paid a dividend of $0.72 per share. This is an increase from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date is Friday, June 26th. Medtronic’s dividend payout ratio is presently 77.21%.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: TD Cowen cut its price target on Medtronic to $100 from $119 but kept a buy rating, signaling the stock still has meaningful upside from current levels. TD Cowen lowers price target on Medtronic
• Positive Sentiment: Another recent bullish note said Medtronic’s guidance is conservative and “built to be beaten,” highlighting strong fiscal 2026 revenue growth and potential upside catalysts from the MiniMed separation, tariff refunds, and payment relief. Medtronic guidance built to be beaten
• Positive Sentiment: Another Seeking Alpha article argued Medtronic is undervalued and that tailwinds are just beginning, reinforcing the idea that investors may be underappreciating the company’s growth potential. Medtronic undervalued and tailwinds just getting started
• Positive Sentiment: Citi also reportedly initiated or reiterated a buy view on Medtronic, adding to the wave of favorable analyst sentiment. Medtronic receives a buy from Citi
• Neutral Sentiment: Medtronic disclosed a voluntary global recall of its Octopus 4 Tissue Stabilizer after an assembly issue affecting 590 units. The issue appears limited, but recalls can create short-term investor caution. Medtronic recalls Octopus 4 Tissue Stabilizer
• Neutral Sentiment: Separate valuation pieces on Medtronic suggest the stock remains cheap relative to fundamentals, but these are more interpretation than hard catalysts for the share price. Medtronic stock could be undervalued

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the sale, the executive vice president owned 37,227 shares of the company’s stock, valued at $2,994,539.88. The trade was a 10.11% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.26% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

MDT has been the subject of a number of research analyst reports. Piper Sandler reiterated a “neutral” rating and set a $85.00 price target on shares of Medtronic in a report on Tuesday, June 16th. Sanford C. Bernstein lowered their price objective on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a research note on Thursday, June 4th. UBS Group dropped their target price on shares of Medtronic from $90.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Jefferies Financial Group reiterated a “hold” rating and set a $88.00 target price on shares of Medtronic in a research note on Thursday, June 4th. Finally, Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a report on Saturday, April 11th. Seventeen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $98.17.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).